Abstract: A system and method for enhancing inferential accuracy of an artificial neural network during training includes during a simulated training of an artificial neural network identifying channel feedback values of a plurality of distinct channels of a layer of the artificial neural network based on an input of a training batch; if the channel feedback values do not satisfy a channel signal range threshold, computing a channel equalization factor based on the channel feedback values; identifying a layer feedback value based on the input of the training batch; and if the layer feedback value does not satisfy a layer signal range threshold, identifying a composite scaling factor based on the layer feedback values; during a non-simulated training of the artificial neural network, providing training inputs of: the training batch; the composite scaling factor; the channel equalization factor; and training the artificial neural network based on the training inputs.

Abstract: A system and method for enhancing inferential accuracy of an artificial neural network during training includes during a simulated training of an artificial neural network identifying channel feedback values of a plurality of distinct channels of a layer of the artificial neural network based on an input of a training batch; if the channel feedback values do not satisfy a channel signal range threshold, computing a channel equalization factor based on the channel feedback values; identifying a layer feedback value based on the input of the training batch; and if the layer feedback value does not satisfy a layer signal range threshold, identifying a composite scaling factor based on the layer feedback values; during a non-simulated training of the artificial neural network, providing training inputs of: the training batch; the composite scaling factor; the channel equalization factor; and training the artificial neural network based on the training inputs.

Abstract: A system and method for enhancing inferential accuracy of an artificial neural network during training includes during a simulated training of an artificial neural network identifying channel feedback values of a plurality of distinct channels of a layer of the artificial neural network based on an input of a training batch; if the channel feedback values do not satisfy a channel signal range threshold, computing a channel equalization factor based on the channel feedback values; identifying a layer feedback value based on the input of the training batch; and if the layer feedback value does not satisfy a layer signal range threshold, identifying a composite scaling factor based on the layer feedback values; during a non-simulated training of the artificial neural network, providing training inputs of: the training batch; the composite scaling factor; the channel equalization factor; and training the artificial neural network based on the training inputs.

Abstract: The present invention discloses novel biocide composition comprising 2,2-dibromo-3-nitrilopropionamide (DBNPA) being in the form of a stable aqueous suspension. Further are disclosed the preparation of these compositions and their biocidal uses.

Abstract: The present invention provides biocide compositions, containing DBNPA encapsulated or absorbed in ceramic powders or xerogels, for preventing the formation of biofilms and for incorporating into paints, coatings, plasters, and plastics.

Abstract: Provided is a method of selectively enzymatically esterifying or selectively enzymatically solvolyzing epimers of analogs of vitamin D having a stereogenic center at C-24 that has a free or esterified OH group. The metod can be used, for example, for separating mixed epimers of the vitamin D analog.

Abstract: The present invention provides 3-benzyloxy-2-aminopyridine (BOPA), 3-(2-Hydroxyethyl)-2-methyl-9-hydoxy-4H-pyrido[1,2-a]pyrimidine-4-one (HMBP), 3-(2-Chloroethyl)-2-methyl-9-hydoxy-4H-pyrido[1,2-a]pyrimidine-4-one (CMHP) and 3-(2-chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrrido[1,2-a]-pyrimidin-4-one (CMHTP) useful as intermediates for the preparation of paliperidone. The present invention also provides processes for preparing these intermediates and for preparing paliperidone.

Abstract: The present invention provides methods of purifying montelukast, a new isolated impurity of montelukast, method for its isolation, and method of using montelukast impurity as a reference marker and a reference standard.

Abstract: The present invention provides methods of purifying montelukast, a new isolated impurity of montelukast, method for its isolation, and method of using montelukast impurity as a reference marker and a reference standard.

Abstract: The present invention provides processes for preparing montelukast.

Abstract: Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, O, P, Q, T, U, V, Y, ?, ?, ?, ?, ?, ?, ? and ?, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.

Abstract: The present invention provides processes of preparing 3-(2-chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrrido[1,2-a]-pyrimidin-4-one (CMHTP) useful as intermediates for the preparation of paliperidone, wherein the processes use 3-(2-chloroethyl)-2-methyl-9-benzyloxy-4H-pyrido[1,2-a]pyrimidine-4-one (CMBP) and/or 3-(2-chloroethyl)-2-methyl-9-hydroxy-4H-pyrido[1,2-a]pyrimidine-4-one (CMHP) having phosphorus at least partially removed as the intermediate.

Abstract: Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, 0, P, Q, T, U, V, Y, ?, ?, ?, ?, ?, ?, ? and ?, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.

Abstract: The present invention provides 3-benzyloxy-2-aminopyridine (BOPA), 3-(2-Hydroxyethyl)-2-methyl-9-hydoxy-4H-pyrido[1,2-a]pyrimidine-4-one (HMBP), 3-(2-Chloroethyl)-2-methyl-9-hydoxy-4H-pyrido[1,2-a]pyrimidine-4-one (CMHP) and 3-(2-chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrrido[1,2-a]- pyrimidin-4-one (CMHTP) useful as intermediates for the preparation of paliperidone. The present invention also provides processes for preparing these intermediates and for preparing paliperidone.

Abstract: Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, O, P, Q, T, U, V, Y, ?, ?, ?, ?, ?, ?, ? and ?, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.

Abstract: Provided is a method of general applicability of epimerizing a vitamin-D analog having an asymmetric allylic carbon atom at the C-24 position. The method is of particular utility in making calcipotriene.

Abstract: The present invention provides methods of purifying montelukast, a new isolated impurity of montelukast, method for its isolation, and method of using montelukast impurity as a reference marker and a reference standard.

Abstract: Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, 0, P, Q, T, U, V, Y, ?, ?, ?, ?, ?, ?, ?, 2 and ?, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.

Abstract: Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, O, P, Q, T, U, V, Y, ?, ?, ?, ?, ?, ?, ? and ?, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.

Abstract: The present invention provides processes for preparing montelukast.